Medicare Coverage Of PET Pharmaceutical Agents Needs Revamp, Industry Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A broad range of stakeholders is asking CMS to remove national non-coverage language for newly approved radiopharmaceuticals used in positron emission tomography to allow speedier access to new tools for diagnosing Alzheimer’s and other diseases.
You may also be interested in...
Medicare Coverage Decision For Amyvid Due July 2013
At Lilly’s request, CMS has agreed to consider expanding the positron imaging tomography tracers that can be covered by Medicare to include agents for imaging beta-amyloid plaques when diagnosing dementia and other neurodegenerative disease.
CMS In Brief
Updates from the 2013 Medicare physician fee schedule and hospital outpatient prospective payment system proposed rules, and other CMS news.
Oncology PET Scan Coverage Expands As CMS Lifts Some Data Mandates
Medicare coverage of PET scans for oncology indications will be less restrictive under a national coverage determination finalized April 3